1035 related articles for article (PubMed ID: 18672400)
1. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
2. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
[TBL] [Abstract][Full Text] [Related]
3. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Huntington Study Group Reach2HD Investigators
Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
6. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG; Ritchie CW; Gunn A; Rembach A; Tsatsanis A; Bedo J; Harrison J; Lannfelt L; Blennow K; Zetterberg H; Ingelsson M; Masters CL; Tanzi RE; Cummings JL; Herd CM; Bush AI
J Alzheimers Dis; 2010; 20(2):509-16. PubMed ID: 20164561
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
[TBL] [Abstract][Full Text] [Related]
8. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
[TBL] [Abstract][Full Text] [Related]
9. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
[TBL] [Abstract][Full Text] [Related]
12. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Crouch PJ; Savva MS; Hung LW; Donnelly PS; Mot AI; Parker SJ; Greenough MA; Volitakis I; Adlard PA; Cherny RA; Masters CL; Bush AI; Barnham KJ; White AR
J Neurochem; 2011 Oct; 119(1):220-30. PubMed ID: 21797865
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
14. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL
Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042
[TBL] [Abstract][Full Text] [Related]
15. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
16. Testing the mettle of PBT2 for Alzheimer's disease.
Relkin NR
Lancet Neurol; 2008 Sep; 7(9):762-3. PubMed ID: 18672401
[No Abstract] [Full Text] [Related]
17. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
Gilman S; Koller M; Black RS; Jenkins L; Griffith SG; Fox NC; Eisner L; Kirby L; Rovira MB; Forette F; Orgogozo JM;
Neurology; 2005 May; 64(9):1553-62. PubMed ID: 15883316
[TBL] [Abstract][Full Text] [Related]
18. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.
Kessler H; Pajonk FG; Bach D; Schneider-Axmann T; Falkai P; Herrmann W; Multhaup G; Wiltfang J; Schäfer S; Wirths O; Bayer TA
J Neural Transm (Vienna); 2008 Dec; 115(12):1651-9. PubMed ID: 18972062
[TBL] [Abstract][Full Text] [Related]
19. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
[TBL] [Abstract][Full Text] [Related]
20. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]